Related Experiment Video
Updated: Nov 27, 2025
The Murine Choline-Deficient, Ethionine-Supplemented CDE Diet Model of Chronic Liver Injury
Published on: October 21, 2017
[¹¹C] choline as a potential PET/CT biomarker of liver cirrhosis: A prospective pilot study
Hemda Schmilovitz-Weiss1, Doron Boltin2, David Groshar3
1Department of Gastroenterology, Rabin Medical Center, Hasharon Hospital, Petach Tikva 4920235, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
Aim Of The Study:
To compare [¹¹C] choline PET/CT findings between patients with cirrhosis and normal liver controls.
Methods:
Included 11 patients with cirrhosis and 14 controls. All underwent a dynamic [11C] choline PET/CT. The maximal standard uptake values (SUVmax), the area under the curve (AUC) and kinetic parameters (K1 and K2), clinical and laboratory data, were compared between groups.
Results:
Patients mean age was 68.4 ± 10.7 and controls, 69.7 ± 7.3 years. Mean SUVmax was higher in patients than controls (right lobe, 10.06 ± 12 vs. 6.3 ± 1.6, P = 0.011; left lobe, 8.6 ± 11.6 vs. 5.4 ± 0.9, P = 0.024; spleen 17.99 ± 27.8 vs. 13.4 ± 2.6, P = 0.027; kidney, 35.9 ± 59.5 vs. 19.3 ± 4.8, P = 0.025) and also AUC values (right lobe, 13,538 ± 20,020 vs. 8427.3 ± 1557.9, P = 0.026; left lobe 12,304 ± 18,871 vs. 6878.9 ± 1294.3, P = 0.024; spleen, 12,875 ± 17,930 vs. 8263.9 ± 1279.2, P = 0.023; kidney, 24,623 ± 36,025 vs. 13,667 ± 3873.9, P = 0.032). No difference in kinetic parameters was found. No correlations between severity of clinical signs and imaging-derived parametric data were found among patients with cirrhosis.
Conclusions:
[11C] choline PET/CT may serve as a noninvasive biomarker for patients with cirrhosis.
